Alan and I were conversing about my question of wh
Post# of 72440
(Total Views: 727)
Posted On: 09/26/2018 2:04:48 PM
Alan and I were conversing about my question of what the B signifies in the clip he posted and it led to a little bit of math on my end. So I figured I'd share:
If AMRN sees peak sales of $2.7B and are therefore potentially valued at $50pps, then given an OS count of 296M shares the company should be worht $14.8B.
I read somewhere when looking into AMRN that the estimated cost of their treatments are expectated to be about ~$2,500 year. This then means they will be treating about 1M patients a year to hit roughly $2.7B in sales.
The 10k says the IPIX OS count was 163M between class A and B stock as of August. I realize the two companies are not apples to apples; however, I think it is fair to say the two companies are comparable in size of market potential as it pertains to the B franchise. I'd be willing to bet that the B franchise will target at least 1 million patients a year between OM, IBD, and antibiotic treatments. Plus I'd bet our cost of treatments will be higher than $2,500 per course.
So, for fun, if IPIX were to get the same type of valuation (not accounting for the fact that we have a much larger and more valuable pipeline), and lets just say for fun we have a little more dilution making OS 170M, then that could put us at $87 per share!! I am VERY ok with that.
Since that doesnt factor in K or P at all, I will target all the naysayers that call out $50-$100 pps target as foolish and wishful thinking to do the math. $50-$100 pps for IPIX is totally reasonable given the market sizes out there. I dont think for one minute that it can be considered stock pumping to throw around these valuations. The math is there and it works.
If AMRN sees peak sales of $2.7B and are therefore potentially valued at $50pps, then given an OS count of 296M shares the company should be worht $14.8B.
I read somewhere when looking into AMRN that the estimated cost of their treatments are expectated to be about ~$2,500 year. This then means they will be treating about 1M patients a year to hit roughly $2.7B in sales.
The 10k says the IPIX OS count was 163M between class A and B stock as of August. I realize the two companies are not apples to apples; however, I think it is fair to say the two companies are comparable in size of market potential as it pertains to the B franchise. I'd be willing to bet that the B franchise will target at least 1 million patients a year between OM, IBD, and antibiotic treatments. Plus I'd bet our cost of treatments will be higher than $2,500 per course.
So, for fun, if IPIX were to get the same type of valuation (not accounting for the fact that we have a much larger and more valuable pipeline), and lets just say for fun we have a little more dilution making OS 170M, then that could put us at $87 per share!! I am VERY ok with that.
Since that doesnt factor in K or P at all, I will target all the naysayers that call out $50-$100 pps target as foolish and wishful thinking to do the math. $50-$100 pps for IPIX is totally reasonable given the market sizes out there. I dont think for one minute that it can be considered stock pumping to throw around these valuations. The math is there and it works.
(13)
(0)Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
Scroll down for more posts ▼